Currently Viewing Posts in Research

Richard M. Jaffee Center for Applied Microbiology: Next-Gen Technology Driving Progress in Livestock Production

Richard M. Jaffee Center for Applied Microbiology Laboratory | Amlan International

Products that prevent pathogenic bacteria from communicating with each other? This is just one of the next‑generation technologies that scientists are developing at Amlan International’s innovative new and improved Richard M. Jaffee Center for Applied Microbiology.

Amlan’s commitment to microbiology research began when their original laboratory opened in 2017 and further strengthened with the expansion of the Richard M. Jaffee Center for Applied Microbiology in October 2019. The new center provides the company with a cutting‑edge facility to accelerate novel animal health and life sciences research. With state-of-the-art equipment, the R&D team can isolate and cultivate both beneficial and pathogenic bacteria and investigate the antimicrobial effects of Amlan’s next‑generation, natural products.

The new lab is a certified Biosafety Level 2 laboratory, equipped with the technical and diagnostic resources of a traditional microbiology lab, as well as molecular biology, immunology and cell biology capabilities. It’s located near the company’s original R&D center, the Nick Jaffee Center for Innovation in Vernon Hills, Illinois. The 6,000-square-foot facility houses the life sciences team and a high‑tech laboratory space.

Novel Approach to No-Antibiotics-Ever Production

By developing innovative animal health solutions for Amlan’s customers, the research team is simultaneously tackling the global issue of antibiotic resistance. The scientists are using an antivirulence approach to control enteric disease in livestock by developing products that can modify pathogen behavior, making them less virulent (friendlier). This antivirulence approach can improve the production and health of flocks or herds while reducing the tendency to select for resistant or mutant bacteria that is seen with the use of conventional antibiotics.

“The new lab allows our life science research team to access a wide variety of state-of-the-art equipment, such as real-time PCR, an anaerobic chamber and florescent microscopy,” says Dr. Hongyu Xue, Life Sciences Director at Amlan. “We are trying to disarm the microbial pathogens by targeting their virulence factors in this facility.”

The life sciences team can also analyze the synergistic capabilities of the company’s proprietary enterosorbent mineral formulated with other feed additives, leading to the development of new products that can provide even greater returns on investment for poultry and livestock producers.

By incorporating best production practices, natural feed additive programs and pioneering innovation that targets virulence factors, producers should be able to reduce inputs in animal diets, enhance intestinal health of food animals and improve production efficiency for the entire industry.

“This new lab enables us to bring new ideas and products to the marketplace like never before,” says Flemming Mahs, President, Amlan International. “Science and research are the foundation of our discovery process to improve animal performance by protecting their intestinal health.”

Stay tuned for more information about the innovative research conducted inside the Richard M. Jaffee Center for Applied Microbiology.

In vitro and in vivo evaluation of therapeutic effects of Neutrapath against Salmonella Typhimurium

Dr. Hongyu Xue's Presentation at the 3rd ATA

H. Xue1*, D. Wang1, B.M. Hargis2; & G. Tellez2

1Amlan International, Chicago, IL, 60061, USA
2Department of Poultry Science, University of Arkansas, Fayetteville AR 72701, USA
*E-mail: Hongyu.Xue@Amlan.com

Source: The 3rd International Symposium on Alternatives to Antibiotics (ATA)

Antibiotic resistance in foodborne pathogens such as Salmonella is a major concern for public health safety. The poultry industry is compelled to seek alternative solutions to antibiotics in reducing the incidence of Salmonella colonization in broiler chickens at the farm level. NeutraPath is a formulated feed additive that features a proprietary blend of essential oils, medium-chain fatty acids and an activated toxin-adsorbing mineral. This formula has been shown to neutralize a variety of key virulence factors of pathogenic bacteria in addition to exerting direct bacteriostatic/bacteriocidal effects. This study was aimed to evaluate in vitro and in vivo effects of NeutraPath on Salmonella enterica sv. Typhimurium (ST) infection in broiler chickens.

An in vitro digestion model was used to simulate three gastrointestinal compartments with physiologically relevant pH and enzymatic conditions correspondent to that of crop, proventriculus and intestinal section respectively. In the in vivo trial, one-day old male broiler chicks were randomly allocated to one of three groups (n=30 chickens), i.e., Challenged control with non-treated feed and NeutraPath supplemented at 0.25% and 0.5% in feed. Chickens were orally gavaged with 106 CFU of live ST per chicken at 9-d old. Twenty-four hours post challenge, ceca-cecal tonsils were removed to evaluate Salmonella recovery and serum was collected for FITC-d determination. Differences between treatments were analyzed using one-way ANOVA.

In the in vitro trial, 0.25% NeutraPath significantly reduced total CFU of ST recovered in the proventriculus and intestinal compartments compared with control (P<0.05). NeutraPath treatment at 0.25% and 0.5% resulted in a 41.7% and 33.3% reduction in the prevalence of ST in ceca respectively compared to the challenged control (P<0.05 for both comparisons). Both dose levels also significantly reduced total ST CFU recovered in the ceca by 1.84 and 1.79 Log10 CFU/g compared to the challenged control (P<0.05 for both comparisons). Further, NeutraPath at both doses significantly reduced serum FITC-dextran levels (P<0.05).

Based on these in vitro and in vivo data, the NeutraPath treatment had the therapeutic potential to reduce ST colonization in broiler chickens and preserve the functional integrity of the intestinal barrier of chickens during ST challenge.

Natural Growth Promoter for Poultry Demonstrates 10:1 ROI, Better than Antibiotics Alone

Featured News Poultry Image

CHICAGO, IL—A recent study found that Varium™, the natural growth promoter for poultry from Amlan International, performed better than antibiotics alone, delivering significant reductions in mortality, and improvements in feed conversion and intestinal health, for a 10:1 return on investment.

“As the reduction or elimination of antibiotics in broiler production continues to expand worldwide, Varium is proving to be an effective way to enhance the growth-promoting abilities of antibiotics, or, when used in antibiotic-free production, to achieve bird performance equivalent to flocks receiving sub-therapeutic levels of antibiotics,” said Dr. Ron Cravens, President of Amlan International, a Nevada Corporation.

“We’re very pleased our customers’ broilers receiving Varium, experienced improved villi height and a reduction in crypt depth indicating improved intestinal integrity,” said Cravens. “It’s quite notable that an improved European Efficiency Index (EEI) score was also seen, increasing from 350 to 400 points.”

Compared to the control diet that included antibiotics, feeding Varium decreased mortality by 40%, from 6.93% to 4.18%, with improvements seen throughout the growout period, not just in young birds. Feed conversion improved 15 points, from 1.64 to 1.49, with the majority of the gains seen after day 7 and a greater response seen in female broilers.

Varium is a registered product in a variety of countries, including China and Mexico. For a full list of registered countries and a complete study of the results and more information on Varium, please visit Amlan.com. Varium is sold outside the U.S.

###

MEDIA CONTACT
Reagan Culbertson
(312) 706-3256
reagan.culbertson@amlan.com

ABOUT AMLAN INTERNATIONAL

Oil-Dri Corporation of America (NYSE: ODC), a Delaware corporation and doing business as “Amlan International,” has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted in its laboratory campus in Vernon Hills, IL. In 2013, the company’s global reach expanded with the establishment of its China subsidiary in Shenzhen. Further information on Amlan International is available at amlan.com.

 

X